Related Experiment Video

Updated: Jun 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC

Andrei Goga1, Dun Yang, Aaron D Tward

  • 1Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California 94143-0552, USA. andrei.goga@ucsf.edu

Nature Medicine
|June 26, 2007
PubMed

Insights

Targeting cyclin-dependent kinase 1 (CDK1) effectively induces apoptosis in MYC-driven cancers by downregulating survivin. This approach shows promise for treating MYC-overexpressing malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Tumor cells exhibit dysregulated cell cycles, making them potential targets for cell cycle kinase inhibitors.
  • Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle progression, and their inhibition is a strategy for cancer therapy.

Purpose of the Study:

  • To investigate the effects of CDK1 inhibition on tumor cells, particularly in the context of MYC oncogenic signaling.
  • To determine if CDK1 inhibition can be a therapeutic strategy for MYC-driven cancers.

Main Methods:

  • Treatment of MYC-transformed cells and other oncogene-transformed cells with small-molecule CDK1 inhibitors.
  • Analysis of apoptosis induction, survivin (BIRC5) expression, and tumor growth in MYC-dependent mouse models.
  • Evaluation of survivin's role in MYC-driven cell survival.

Main Results:

  • CDK1 inhibition induced rapid apoptosis specifically in MYC-transformed cells, but not in cells with other oncogenic signals.
  • CDK1 inhibition led to decreased survivin expression and MYC-dependent apoptosis.
  • Treatment with CDK1 inhibitors reduced tumor growth and improved survival in MYC-dependent mouse lymphoma and hepatoblastoma models.

Conclusions:

  • CDK1 inhibition is a potent inducer of apoptosis in MYC-overexpressing cancer cells.
  • Survivin downregulation is a key mechanism by which CDK1 inhibition triggers apoptosis in these cells.
  • CDK1 inhibition represents a promising therapeutic strategy for human malignancies characterized by MYC overexpression, especially given the lack of direct MYC pathway inhibitors.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...